ParaZero Integrates its Safety Technology into Draganfly’s Commander 3XL Drones for Home Hospital Delivery and Emergency Response Tel Aviv, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "Company” or “ParaZero”), an aerospace company focused on drone safety systems for commercial drones and urban air mobility aircraft, today announced a strategic collaboration with Draganfly Inc. (Nasdaq: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly”), an industry pioneer in commercial drone technology, integrating its advanced safety technology into Draganfly’s C...
Draganfly Integrates ParaZero Safety Technology into Commander 3XL Drones for Home Hospital Delivery and Emergency Response San Diego, CA., April 25, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer is pleased to announce a strategic collaboration with ParaZero Technologies Ltd., (NASDAQ: PRZO) a pioneer in drone safety systems aimed at enhancing the safety and efficacy of UAVs in medical and emergency response operations. The integration of Draganfly and...
A director at Zhengwei Group Holdings Company Limited sold 13,384,000 shares at 0.218HKD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
Three Directors at Biokarpet S.A sold 300,000 shares at 2.740EUR. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
NGS Group AB (publ): Delårsrapport januari-mars 2024 Paradigmskifte inom sjuksköterskebemanning i Sverige. Full kraft i Norgeexpansion. Beslut om nyemissioner. Första kvartalet i sammandrag Nettoomsättningen för första kvartalet uppgick till 100 MSEK (141), en minskning med 29%.Rörelseresultatet (EBITDA) för första kvartalet uppgick till -5,5 MSEK (-1,6), rörelsemarginal -5,5% (-1,1).Rörelseresultatet (EBIT) för första kvartalet uppgick till -6,8 MSEK (-2,7), rörelsemarginal -6,8% (-1,9).Resultatet för första kvartalet uppgick till -6,3 MSEK (-2,8).Resultatet per aktie före och...
Altisource Announces First Quarter 2024 Financial Results LUXEMBOURG, April 25, 2024 (GLOBE NEWSWIRE) -- Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider and marketplace for the real estate and mortgage industries, today reported financial results for the first quarter 2024. “I am very pleased with our first quarter performance. We generated $4.6 million of Adjusted EBITDA(1), marking our best quarterly performance since the third quarter of 2020, on $36.9 million of service revenue. We are winning meaningful new business and ramping ...
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:0...
Nasdaq Announces 9% Increase in Quarterly Dividend to $0.24 Per Share NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.24 per share on the company's outstanding common stock, a 9% increase from the previous quarter. The dividend is payable on June 28, 2024 to shareholders of record at the close of business on June 14, 2024. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq N...
Corero has secured $8m of orders from both existing and new customers in the first four months of FY24E. The group reported a 17% YoY growth rate in annualised recurring revenue (ARR) last year. This level of momentum in orders not only supports our double-digit % growth forecasts, but also validates the Group’s go-to-market strategy. We are forecasting +13% growth in revenues in FY24E to $25.3m (unchanged), With gross margins high at 90%, the drop through rate of incremental revenues to earnin...
Valley National Bancorp Announces First Quarter 2024 Results NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, today reported net income for the first quarter 2024 of $96.3 million, or $0.18 per diluted common share, as compared to the fourth quarter 2023 net income of $71.6 million, or $0.13 per diluted common share, and net income of $146.6 million, or $0.28 per diluted common share, for the first quarter 2023. Excluding all non-core income and charges, our adjusted net income (a non-GAAP measure) was $99.4 m...
A director at Luk Fook Holdings (International) Ltd bought 600,000 shares at 17.957HKD and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET. To access the May 2 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s co...
Sandy Spring Bancorp Declares Quarterly Dividend OLNEY, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Sandy Spring Bancorp, Inc., (Nasdaq- SASR), the parent company of Sandy Spring Bank, announced that the board of directors declared a quarterly common stock dividend of $0.34 per share payable on May 15, 2024 to shareholders of record on May 8, 2024. This dividend is consistent with the previous linked quarter and the second quarter of 2023. About Sandy Spring Bancorp, Inc./Sandy Spring Bank Sandy Spring Bancorp, Inc., headquartered in Olney, Maryland, is the holding company for Sandy Spr...
Pool Corporation Reports First Quarter Results Highlights Net sales of $1.1 billion exceeded $1.0 billion in the first quarter for the fourth consecutive yearOperating income of $108.7 million with a solid operating margin of 9.7%Net cash provided by operations improved 41% to a Q1 record $145.4 millionQ1 2024 diluted EPS of $2.04 or $1.85 without tax benefits Updates annual earnings guidance range to $13.19 to $14.19 per diluted share to reflect additional tax benefits COVINGTON, La., April 25, 2024 (GLOBE NEWSWIRE) -- Pool Corporation (Nasdaq/GSM:POOL) today reported results for the f...
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet® NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an upd...
First Northwest Bancorp Reports First Quarter 2024 Financial Results PORT ANGELES, Wash., April 25, 2024 (GLOBE NEWSWIRE) -- "The company returned to profitability in Q1 2024 following the first step of our balance sheet restructure in the fourth quarter of 2023," said Matthew P. Deines, President and CEO. "We continue to execute on this strategy as we added over $90 million in current market rate loans and securities over the course of the first quarter. We will continue this strategy in the second quarter as we prepare to execute on a sale-leaseback transaction for six of our branches l...
Nasdaq Reports First Quarter 2024 Results; Strong Execution Delivers Double-Digit Solutions Revenue Growth NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today reported financial results for the first quarter of 2024. First quarter 2024 net revenues1 were $1.1 billion, an increase of 22% over the first quarter of 2023, up 6% organically2 or 7% on a pro forma3 basis, including Adenza in the first quarter of 2023 results for Nasdaq. This included Solutions4 revenue increasing 35%, with organic growth of 11% or 13% on a pro forma basis.Annualized Recurring Revenue ...
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interi...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Intevac, Inc. (Nasdaq: IVAC) today reported financial results for the first quarter ended March 30, 2024. Q1 Highlights: Continued strong demand for technology upgrades for hard disk drive (HDD) media resulted in sales of nearly $10 million and gross margin approaching 44% for the quarter. New orders exceeded $20 million for the quarter, and included HDD technology upgrade bookings from multiple customers, including initial HAMR (heat-assisted magnetic recording) upgrade orders from a leading data storage company. Completed agreement related to...
Tecnoglass Sets Date for First Quarter 2024 Results Miami, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Tecnoglass, Inc. (NYSE: TGLS) ("Tecnoglass" or the "Company"), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced it will release financial results for the first quarter 2024 before the market opens on Thursday, May 9, 2024. Management will host a webcast and conference call that same day at 10:00 a.m. Eastern time to review the Company’s results. Webcast and Conference Call The con...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.